These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34449255)

  • 1. Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sjögren's Syndrome.
    Kim J; Moon TK; Yoon HJ; Ji YS; Yoon KC
    J Ocul Pharmacol Ther; 2021 Oct; 37(8):472-478. PubMed ID: 34449255
    [No Abstract]   [Full Text] [Related]  

  • 2. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren's syndrome versus non-Sjogren's syndrome.
    Cubuk MO; Ucgul AY; Ozgur A; Ozulken K; Yuksel E
    Int Ophthalmol; 2021 Apr; 41(4):1479-1485. PubMed ID: 33484384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
    Leonardi A; Messmer EM; Labetoulle M; Amrane M; Garrigue JS; Ismail D; Sainz-de-la-Maza M; Figueiredo FC; Baudouin C
    Br J Ophthalmol; 2019 Jan; 103(1):125-131. PubMed ID: 29545413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
    Leonardi A; Van Setten G; Amrane M; Ismail D; Garrigue JS; Figueiredo FC; Baudouin C
    Eur J Ophthalmol; 2016 Jun; 26(4):287-96. PubMed ID: 27055414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of intense pulsed light combined with topical 0.05% Cyclosporin A eyedrops in the treatment of Sjögren's syndrome related dry eye.
    Huo Y; Huang X; Lin L; Yang S; Qin Z; Yirui Z; Mou Y; Jin X
    Expert Rev Clin Immunol; 2024 Oct; 20(10):1261-1267. PubMed ID: 38785065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye.
    Daull P; Nagano T; Gros E; Feraille L; Barabino S; Garrigue JS
    Curr Eye Res; 2021 Aug; 46(8):1096-1104. PubMed ID: 33588656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy of Diquafosol Ophthalmic Solution in Non-Sjögren and Sjögren Syndrome Dry Eye Patients Unresponsive to Artificial Tear.
    Jeon HS; Hyon JY
    J Ocul Pharmacol Ther; 2016 Sep; 32(7):463-8. PubMed ID: 27294831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
    Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
    Labetoulle M; Leonardi A; Amrane M; Ismail D; Garrigue JS; Garhöfer G; de la Maza MS; Baudouin C
    Clin Ther; 2018 Nov; 40(11):1894-1906. PubMed ID: 30389343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical fluorometholone treatment for ocular dryness in patients with Sjögren syndrome: a randomized clinical trial in China.
    Lin T; Gong L
    Medicine (Baltimore); 2015 Feb; 94(7):e551. PubMed ID: 25700323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study.
    Moscovici BK; Holzchuh R; Sakassegawa-Naves FE; Hoshino-Ruiz DR; Albers MB; Santo RM; Hida RY
    Cont Lens Anterior Eye; 2015 Oct; 38(5):373-8. PubMed ID: 25956572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world insights and outcomes related to ciclosporin A 0.1% cationic emulsion for the long-term treatment of dry eye disease in Germany: Country-level sub-analysis of the PERSPECTIVE study.
    Lanzl I; Deuter CME; Lorenz K; Geerling G;
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct; 262(10):3261-3271. PubMed ID: 38722320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops (II) in the Treatment of Dry Eye Associated with Primary Sjögren's Syndrome.
    Gao M; Zhao L; Liang R; Zhu Q; Zhao Q; Kong X
    Ocul Immunol Inflamm; 2023 Oct; 31(8):1662-1668. PubMed ID: 35914303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen.
    Chan YH; Sun CC
    Taiwan J Ophthalmol; 2023; 13(1):68-74. PubMed ID: 37252163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction.
    Prabhasawat P; Tesavibul N; Mahawong W
    Cornea; 2012 Dec; 31(12):1386-93. PubMed ID: 23135530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.
    Baudouin C; Figueiredo FC; Messmer EM; Ismail D; Amrane M; Garrigue JS; Bonini S; Leonardi A
    Eur J Ophthalmol; 2017 Aug; 27(5):520-530. PubMed ID: 28362054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome.
    Yavuz S; Asfuroğlu E; Bicakcigil M; Toker E
    Rheumatol Int; 2011 Aug; 31(8):1045-9. PubMed ID: 20309693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
    Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
    Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased corneal sub-basal nerve density in patients with Sjögren syndrome treated with topical cyclosporine A.
    Levy O; Labbé A; Borderie V; Hamiche T; Dupas B; Laroche L; Baudouin C; Bouheraoua N
    Clin Exp Ophthalmol; 2017 Jul; 45(5):455-463. PubMed ID: 27957797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.